Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Par Drugs IPO is a fixed price issue of ₹8.53 crores. The issue is entirely a fresh issue of 0.17 crore shares of ₹8.53 crore.
Par Drugs IPO bidding started from May 3, 2019 and ended on May 8, 2019. The allotment for Par Drugs IPO was finalized on May 13, 2019. The shares got listed on NSE SME on May 16, 2019.
Par Drugs IPO price is ₹51.00 per share . The lot size for an application is 2,000. The minimum amount of investment required by an individual investor (retail) is ₹1,02,000 (2000 shares). The minimum lot size investment for HNI is 2 lots (4,000 shares), amounting to ₹2,04,000.
The issue includes a reservation of up to 30,000 shares for employees offered at a discount of ₹0.00 to the issue price.
Pantomath Capital Advisors Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. The market maker of the company is Pantomath Stock Brokers Pvt.Ltd..
Refer to Par Drugs IPO RHP for detailed Information.
| IPO Date | May 3, 2019 to May 8, 2019 |
| Listing Date | May 16, 2019 |
| Face Value | ₹10 per share |
| Issue Price Band | |
| Issue Price Final | ₹51 per share |
| Lot Size | 2,000 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 16,72,000 shares (aggregating up to ₹8.53 Cr) |
| Reserved for Market Maker | 84,000 shares Pantomath Stock Brokers Pvt.Ltd. (aggregating up to ₹0.4284 Cr) |
| Net Offered to Public | 15,88,000 shares (aggregating up to ₹8.10 Cr) |
| Issue Type | Fixed Price IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 44,80,318 shares |
| Share Holding Post Issue | 61,52,318 shares |
Par Drugs IPO offers total 16,72,000 shares. Out of which 7,78,000 (46.53%) allocated to NII, 7,80,000 (46.65%) allocated to RII.
| Investor Category | Shares Offered |
|---|---|
| Market Maker Shares Offered | 84,000 (5.02%) |
| NII (HNI) Shares Offered | 7,78,000 (46.53%) |
| Retail Shares Offered | 7,80,000 (46.65%) |
| Employee Shares Offered | 30,000 (1.79%) |
| Total Shares Offered | 16,72,000 (100.00%) |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only NII | Above Rs 2 Lakhs | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Par Drugs IPO opens on May 3, 2019, and closes on May 8, 2019.
| IPO Open Date | Fri, May 3, 2019 |
| IPO Close Date | Wed, May 8, 2019 |
| Tentative Allotment | Mon, May 13, 2019 |
| Initiation of Refunds | Tue, May 14, 2019 |
| Credit of Shares to Demat | Wed, May 15, 2019 |
| Tentative Listing Date | Thu, May 16, 2019 |
| Cut-off time for UPI mandate confirmation | 5 PM on Wed, May 8, 2019 |
Investors can bid for a minimum of 2,000 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 2,000 | ₹1,02,000 |
| Retail (Max) | 1 | 2,000 | ₹1,02,000 |
| HNI (Min) | 2 | 4,000 | ₹2,04,000 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in 1999, Gujarat based Par Drugs and Chemicals Limited is engaged in the business of manufacturing and developing active pharma ingredients (API) for the Indian and international markets. APIs are used as the main ingredient in making tablets, capsules, and other finished dosages. The company also produces various antacid molecules.
It has two manufacturing facilities located at Ankleshwar and Bhavnagar in Gujarat. Currently, the company has a total of 6 Fine Chemical and 12 API products which are available in the market of 17 countries, including India. Some of the customers of the company are Dabur India Ltd, Meyer Organics Pvt. Ltd, Cadila Healthcare Ltd., Cipla Ltd, and Pfizer Ltd. For fiscal 2018, the international and domestic operations recorded 86.88% and 13.12%, respectively from the total company sales.
The company has a testing laboratory to maintain quality standards for finished products and raw materials. Par Drugs and Chemicals Ltd also performs drying operations of the products provided by customers in the liquid form and converts them into powders.
The competitive strengths of the company are:
1. Diversified product range
2. International presence
3. Prompt sales & distribution network
4. A good track record
5. Strong chemistry capabilities
| Particulars | For the year/period ended (in Rs. Lakhs) | ||||
|---|---|---|---|---|---|
| 31-Mar-19 | 31-Mar-18 | 31-Mar-17 | 31-Mar-16 | ||
| Total Assets | 5,135.55 | 5,393.89 | 5,604.14 | 5,803.08 | |
| Total Revenue | 4,641.20 | 4,241.65 | 4,880.90 | 3,326.43 | |
| Profit After Tax | 241.88 | 149.53 | 184.78 | 42.18 | |
The Company Par Drugs IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Funding working capital requirements of the Company | 7.00 |
| 2 | General Corporate Purpose | 0.89 |
[Dilip Davda] Investors may consider investment for the long term. Based on financial parameters (including P/BV data) issue appears reasonably priced. Promoters have converted shares at Rs. 66 while the issue is priced lower. Employees too are offered shares at the same price of IPO. Read detail review...
| Listing Date | May 16, 2019 |
| BSE Script Code | |
| NSE Symbol | PAR |
| ISIN | INE04LG01015 |
| Final Issue Price | ₹51 per share |
| Price Details | NSE SME |
|---|---|
| Final Issue Price | ₹51.00 |
| Open | ₹52.90 |
| Low | ₹50.30 |
| High | ₹52.90 |
| Last Trade | ₹50.45 |
Par Drugs & Chemicals Ltd.
805, Dwarkesh Complex
R.C. Dutt Road
Alkapuri
Vadodara, Gujarat, 390007
Phone: +91 265 2332018
Email: cs.sanket@pardrugs.com
Website: http://pardrugs.com/
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: pardrugs.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Par Drugs IPO is a SME IPO of 16,72,000 equity shares of the face value of ₹10 aggregating up to ₹8.53 Crores. The issue is priced at ₹51 per share. The minimum order quantity is 2000.
The IPO opens on May 3, 2019, and closes on May 8, 2019.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Par Drugs IPO using UPI as a payment gateway. Zerodha customers can apply in Par Drugs IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Par Drugs IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Par Drugs IPO opens on May 3, 2019 and closes on May 8, 2019.
Par Drugs IPO lot size is 2000, and the minimum amount required for application is ₹1,02,000.
You can apply in Par Drugs IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Par Drugs IPO will be done on Monday, May 13, 2019, and the allotted shares will be credited to your demat account by Wednesday, May 15, 2019. Check the Par Drugs IPO allotment status.
The Par Drugs IPO listing date is on Thursday, May 16, 2019.
Useful Articles
RHP